Total Payments
$35,385
2024 Payments
$340.35
Companies
8
Transactions
37
Medicare Patients
577
Medicare Billing
$92,125
Payment Breakdown by Category
Consulting$15,428 (43.6%)
Research$10,279 (29.1%)
Other$7,665 (21.7%)
Travel$1,459 (4.1%)
Food & Beverage$540.13 (1.5%)
Education$12.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,428 | 4 | 43.6% |
| Unspecified | $10,279 | 13 | 29.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,665 | 8 | 21.7% |
| Travel and Lodging | $1,459 | 4 | 4.1% |
| Food and Beverage | $540.13 | 7 | 1.5% |
| Education | $12.99 | 1 | 0.0% |
Payments by Type
General
$25,106
24 transactions
Research
$10,279
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $10,727 | 12 | $0 (2024) |
| Astellas Pharma Global Development | $10,279 | 13 | $0 (2023) |
| PFIZER INC. | $7,310 | 5 | $0 (2019) |
| Eli Lilly and Company | $5,282 | 3 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $1,500 | 1 | $0 (2021) |
| Coherus Biosciences Inc. | $140.35 | 1 | $0 (2024) |
| Genentech USA, Inc. | $133.45 | 1 | $0 (2023) |
| Eisai Inc. | $12.99 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $340.35 | 2 | GENZYME CORPORATION ($200.00) |
| 2023 | $1,396 | 3 | Astellas Pharma Global Development ($1,262) |
| 2022 | $1,848 | 3 | Astellas Pharma Global Development ($1,723) |
| 2021 | $10,526 | 8 | Astellas Pharma Global Development ($5,001) |
| 2020 | $6,426 | 6 | GENZYME CORPORATION ($2,876) |
| 2019 | $8,896 | 9 | GENZYME CORPORATION ($7,496) |
| 2018 | $4,643 | 4 | PFIZER INC. ($4,600) |
| 2017 | $1,310 | 2 | PFIZER INC. ($1,310) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/12/2024 | GENZYME CORPORATION | CAPRELSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 03/01/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $140.35 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 08/21/2023 | Astellas Pharma Global Development | Padcev (Drug) | — | Cash or cash equivalent | $822.90 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: Oncology | ||||||
| 06/04/2023 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $133.45 | General |
| Category: BioOncology | ||||||
| 02/17/2023 | Astellas Pharma Global Development | Padcev (Drug) | — | Cash or cash equivalent | $439.50 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: Oncology | ||||||
| 07/21/2022 | Astellas Pharma Global Development | Padcev (Drug) | — | In-kind items and services | $1,095.00 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Maligt Solid Tumors (EV-202) • Category: Oncology | ||||||
| 03/15/2022 | GENZYME CORPORATION | CAPRELSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $125.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 03/03/2022 | Astellas Pharma Global Development | Padcev (Drug) | — | In-kind items and services | $627.85 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Maligt Solid Tumors (EV-202) • Category: Oncology | ||||||
| 12/14/2021 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $958.12 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: ONCOLOGY | ||||||
| 11/12/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,025.00 | General |
| 10/15/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 08/23/2021 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $958.12 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: ONCOLOGY | ||||||
| 07/26/2021 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $1,227.50 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: ONCOLOGY | ||||||
| 07/26/2021 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $549.37 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: ONCOLOGY | ||||||
| 07/26/2021 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $549.37 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: ONCOLOGY | ||||||
| 03/11/2021 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $758.33 | Research |
| Study: An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) • Category: ONCOLOGY | ||||||
| 11/17/2020 | GENZYME CORPORATION | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,876.00 | General |
| Category: Oncology | ||||||
| 05/20/2020 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $822.50 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) • Category: ONCOLOGY | ||||||
| 04/20/2020 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $712.50 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) • Category: ONCOLOGY | ||||||
| 02/17/2020 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $758.33 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) • Category: ONCOLOGY | ||||||
| 02/03/2020 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $127.36 | General |
| 01/15/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $1,129.33 | General |
| 06/22/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Consulting Fee | Cash or cash equivalent | $7,027.00 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Travel and Lodging | Cash or cash equivalent | $194.88 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $112.16 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Astellas Pharma Global Development | $6,263 | 8 |
| AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202) | Astellas Pharma Global Development | $2,293 | 3 |
| An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Maligt Solid Tumors (EV-202) | Astellas Pharma Global Development | $1,723 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 117 | 247 | $114,132 | $23,686 |
| 2022 | 5 | 137 | 269 | $120,103 | $25,265 |
| 2021 | 5 | 156 | 252 | $107,803 | $24,990 |
| 2020 | 7 | 167 | 256 | $83,969 | $18,183 |
Total Patients
577
Total Services
1,024
Medicare Billing
$92,125
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 72 | 196 | $95,315 | $20,209 | 21.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 22 | 22 | $14,641 | $2,823 | 19.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 23 | 29 | $4,176 | $653.86 | 15.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 67 | 181 | $84,889 | $18,497 | 21.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 24 | 24 | $14,928 | $3,062 | 20.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 26 | $10,166 | $1,990 | 19.6% |
| 99358 | Extended patient service without direct patient contact, first hour | Facility | 2022 | 14 | 14 | $6,664 | $1,165 | 17.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 21 | 24 | $3,456 | $551.75 | 16.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 62 | 151 | $67,346 | $16,266 | 24.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 33 | 33 | $19,536 | $4,455 | 22.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 26 | 29 | $8,120 | $2,071 | 25.5% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2021 | 22 | 22 | $10,472 | $1,782 | 17.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 13 | 17 | $2,329 | $417.21 | 17.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 47 | 100 | $26,600 | $5,783 | 21.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 28 | 51 | $21,624 | $4,251 | 19.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $11,823 | $2,729 | 23.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 29 | 42 | $8,384 | $2,428 | 29.0% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 18 | 18 | $8,568 | $1,558 | 18.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 12 | 12 | $5,124 | $1,000 | 19.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 12 | 12 | $1,846 | $433.65 | 23.5% |
About Justine Bruce
Justine Bruce is a Hospice and Palliative Medicine healthcare provider based in Madison, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164518692.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Justine Bruce has received a total of $35,385 in payments from pharmaceutical and medical device companies, with $340.35 received in 2024. These payments were reported across 37 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($15,428).
As a Medicare-enrolled provider, Bruce has provided services to 577 Medicare beneficiaries, totaling 1,024 services with total Medicare billing of $92,125. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospice and Palliative Medicine
- Other Specialties Medical Oncology
- Location Madison, WI
- Active Since 10/04/2006
- Last Updated 01/28/2021
- Taxonomy Code 207RH0002X
- Entity Type Individual
- NPI Number 1164518692
Products in Payments
- LIBTAYO (Drug) $7,496
- INLYTA (Drug) $7,310
- PADCEV (Drug) $7,294
- Padcev (Drug) $2,985
- LIBTAYO (Biological) $2,876
- CAPRELSA (Drug) $325.00
- Udenyca (Biological) $140.35
- Alecensa (Biological) $133.45
- ELITEK (Drug) $30.00
- Lenvima (Drug) $12.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospice and Palliative Medicine Doctors in Madison
Dr. Toby Campbell, M.d., Msci, M.D., MSCI
Hospice and Palliative Medicine — Payments: $19,362
Hospice and Palliative Medicine $19,362
John Miller, M.d, M.D
Hospice and Palliative Medicine — Payments: $94.29
Hospice and Palliative Medicine $94.29
Peter Mahler, Md Phd, MD PHD
Hospice and Palliative Medicine — Payments: $12.58
Hospice and Palliative Medicine $12.58
James Haine, Md, MD
Hospice and Palliative Medicine
Hospice and Palliative Medicine
James Cleary, Md, MD
Hospice and Palliative Medicine
Hospice and Palliative Medicine
Ann Catlett, Md, MD
Hospice and Palliative Medicine
Hospice and Palliative Medicine